Stem definition | Drug id | CAS RN |
---|---|---|
anthelminthics, tiabendazole derivatives | 1641 | 31431-39-7 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 22 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 15 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 28, 1974 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 116.26 | 49.11 | 40 | 334 | 108172 | 46577516 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|
Source | Code | Description |
---|---|---|
ATC | P02CA01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
ATC | P02CA51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
FDA EPC | N0000175481 | Anthelmintic |
MeSH PA | D000871 | Anthelmintics |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D050256 | Antimitotic Agents |
MeSH PA | D000969 | Antinematodal Agents |
MeSH PA | D000977 | Antiparasitic Agents |
MeSH PA | D050257 | Tubulin Modulators |
CHEBI has role | CHEBI:35444 | antinematodals |
CHEBI has role | CHEBI:60832 | tubulin modulators |
CHEBI has role | CHEBI:61951 | microtubule destabilising role |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Ascariasis | indication | 2435008 | DOID:456 |
Trichuriasis | indication | 3752003 | |
Enterobiasis | indication | 266162007 | |
Ancylostoma Duodenale Infection | indication | ||
Necator Americanus Infection | indication | ||
Infection by Gnathostoma | off-label use | 44086001 | DOID:11379 |
Capillaria infection | off-label use | 52979002 | DOID:12474 |
Echinococcus granulosus infection | off-label use | 75006000 | DOID:1495 |
Echinococcus multilocularis | off-label use | 86648009 | |
Infection by larvae of Trichinella spiralis | off-label use | 88264003 | |
Angiostrongyliasis due to Angiostrongylus cantonensis | off-label use | ||
Angiostrongyliasis due to Angiostrongylus costaricensis | off-label use | ||
Disease of liver | contraindication | 235856003 | DOID:409 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.61 | acidic |
pKa2 | 13.2 | acidic |
pKa3 | 2.93 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Tyrosine-protein kinase ABL1 | Kinase | Ki | 5.34 | CHEMBL | |||||
Vascular endothelial growth factor receptor 2 | Kinase | IC50 | 5.44 | CHEMBL | |||||
Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
Tubulin | Structural | INHIBITOR | CHEMBL | CHEMBL | |||||
Calmodulin-domain protein kinase 1 | Kinase | IC50 | 6.17 | CHEMBL |
ID | Source |
---|---|
4019270 | VUID |
N0000147469 | NUI |
D00368 | KEGG_DRUG |
4019270 | VANDF |
C0025023 | UMLSCUI |
CHEBI:6704 | CHEBI |
CHEMBL685 | ChEMBL_ID |
D008463 | MESH_DESCRIPTOR_UI |
DB00643 | DRUGBANK_ID |
2942 | INN_ID |
81G6I5V05I | UNII |
4030 | PUBCHEM_CID |
202972 | RXNORM |
1672 | MMSL |
5026 | MMSL |
789 | MMSL |
d00154 | MMSL |
002987 | NDDF |
387311004 | SNOMEDCT_US |
56059005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
VERMOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50458-675 | TABLET, CHEWABLE | 500 mg | ORAL | NDA | 27 sections |
MEBENDAZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3732 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 21 sections |
Emverm | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64896-669 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 26 sections |